Shopping Cart
Remove All
Your shopping cart is currently empty
S07-2010 is an AKR1C3 inhibitor with potential anti-cancer activity, suppressing AKR1C3, AKR1C4, AKR1C1, and AKR1C2, inducing apoptosis in A549/DDP cells. S07-2010 exhibits significant cytotoxicity in MCF-7/DOX and A549/DDP.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 2 mg | $52 | In Stock | In Stock |
| Description | S07-2010 is an AKR1C3 inhibitor with potential anti-cancer activity, suppressing AKR1C3, AKR1C4, AKR1C1, and AKR1C2, inducing apoptosis in A549/DDP cells. S07-2010 exhibits significant cytotoxicity in MCF-7/DOX and A549/DDP. |
| Targets&IC50 | AKR1C3:0.19 μM, AKR1C2:0.73 μM, AKR1C4:0.36 μM, AKR1C1:0.47 μM |
| In vitro | S07-2010 (0-25 μM, 48h) was shown to be cytotoxic to MCF-7/DOX and A549/DDP with IC50 = 127.5 and 5.51 μM. In A549/DDP cells, S07-2010 can significantly reverse cancer cell resistance to DDP and inhibit tumor proliferation at low concentrations. In A549/DDP cells, the CI values of S07-2010 ranged from 0.2 to 0.6, indicating a strong synergistic drug effect in the combination therapy. S07-2010 (25 μM) can induce apoptosis of tumor cells. [1] |
| Synonyms | S072010 |
| Molecular Weight | 371.45 |
| Formula | C19H21N3O3S |
| Cas No. | 1223194-71-5 |
| Smiles | O=C1N=C(SCC(=O)C2=CC=C3NC(=O)CCCC3=C2)NC(=C1)CCC |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 30 mg/mL (80.76 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.38 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.